Newguy49, I can see the cause of confusion between subsidiaries as Chris Wagner, EMHTF's CEO has been discussing "new products, protected products, new multi-billion dollar markets...." and "applying a new toolbox of bioengineering, randomized control trials, etc." to marijuana. Here is an interesting candid interview with him where he discusses the future for product development initiatives.....and it is a bit unclear whether all of this would actually fit under the "Botanicals" and/or "Theraputics" umbrellla of EMHTF:
I imagine there may be potential for intracompany collaborations, licensing agreements, and raw material supply agreements between the Emerald Health family of companies.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.